Skip to main content
OpenTrials
Completed

NCT Number: NCT04952883

Hydrogen Sulfide and Pulmonary Vascular Remodeling on HRCT in Patients With COPD

HRCT was used to evaluate pulmonary vascular remodeling in COPD. The role of H2S in pulmonary vascular remodeling in COPD was analyzed, in order to provide a basis for seeking new therapeutic targets.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University Third Hospital

Beijing, China

About this study

This study aimed to investigate the relationship between endogenous H2S and pulmonary vascular remodeling on HRCT in patients with COPD through the determination of H2S and its synthase mRNA levels in blood and pulmonary vessels by HRCT, to evaluate the role of H2S in pulmonary vascular remodeling in COPD and to provide a basis for seeking new therapeutic targets. This study had predictive value for clinical prognosis of patients. It had important clinical guiding significance and social and economic benefit to comprehensively understand the pathogenesis of COPD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meet the GOLD 2016 guidelines for diagnostic criteria of COPD: dyspnea, chronic cough and/or sputum symptoms, exposure to risk factors, and pulmonary function after inhalation of bronchodilator with forced expiratory volume (FEV1)/forced vital capacity (FVC) < 70%.

Exclusion criteria

  • 1. Other lung diseases such as pneumonia, lung cancer, tuberculosis, pulmonary embolism, heart diseases such as heart failure, ventricular septal defect, patent ductus arteriosus, thoracic deformity and pleural diseases.
  • Patients who are unable to understand and/or complete questionnaire.

Treatment and study plan

Primary outcomes

  1. Plasma levels of H2S and its synthase nucleic acid and pulmonary vascular remodeling indexes on HRCT in COPD patients

    Time frame: 1 year

Secondary outcomes

  1. Relationship between plasma H2S and its synthase nucleic acid levels and pulmonary vascular remodeling indexes on HRCT in patients with COPD

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

A Cross-sectional Study of Endogenous Hydrogen Sulfide and Pulmonary Vascular Remodeling on HRCT in Patients With Chronic Obstructive Pulmonary Disease

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jul 7, 2021
Registry last updated
Jul 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.